Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' BELLDEGRUN A' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 103 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Gitlitz, BJ; Hoffman, DMJ; Moldawer, N; Belldegrun, A; Figlin, RA
      Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: An analysis of 124 consecutively treated patients

      CANCER JOURNAL
    2. Belldegrun, A
      What's hot in the prostate?

      PROSTATE CANCER AND PROSTATIC DISEASES
    3. Belldegrun, A; Tso, CL; Zisman, A; Naitoh, J; Said, J; Pantuck, AJ; Hinkel, A; de Kernion, J; Figlin, R
      Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial andbasic biology

      HUMAN GENE THERAPY
    4. Wu, L; Matherly, J; Smallwood, A; Adams, JY; Billick, E; Belldegrun, A; Carey, M
      Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors

      GENE THERAPY
    5. Pantuck, AJ; Zisman, A; Belldegrun, A
      Gene and immune therapy for renal cell carcinoma

      INTERNATIONAL JOURNAL OF UROLOGY
    6. Pantuck, AJ; Zisman, A; Henderson, D; Wilson, D; Schreiber, A; Belldegrun, A
      New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions

      UROLOGY
    7. Belldegrun, A; Bander, NH; Lerner, SP; Wood, DP; Pantuck, AJ
      Society of urologic oncology biotechnology forum: New approaches and targets for advanced prostate cancer

      JOURNAL OF UROLOGY
    8. Tso, CL; Zisman, A; Pantuck, A; Calilliw, R; Hernandez, JM; Paik, S; Nguyen, D; Gitlitz, B; Shintaku, PI; de Kernion, S; Figlin, R; Belldegrun, A
      Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 andGranulocyte/Monocyte-Colony stimulating factor

      CANCER RESEARCH
    9. Patel, B; Belldegrun, A
      Interferon alpha, GM-CSF-Activated T cells, and IL-6 in renal cell carcinoma

      RENAL CANCER
    10. Zisman, A; Pantuck, AJ; Belldegrun, A
      Gene and immune-based therapies for genitourinary malignancies: Current status and future prospects

      ISRAEL MEDICAL ASSOCIATION JOURNAL
    11. Tso, CL; McBride, WH; Sun, JR; Patel, B; Tsui, KH; Paik, SH; Gitlitz, B; Caliliw, R; van Ophoven, A; Wu, L; deKernion, J; Belldegrun, A
      Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells

      CANCER JOURNAL
    12. Hinkel, A; Tso, CL; Gitlitz, BJ; Neagos, N; Schmid, I; Paik, SH; deKernion, J; Figlin, R; Belldegrun, A
      Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma

      JOURNAL OF IMMUNOTHERAPY
    13. Belldegrun, A
      What's hot in the prostate?

      PROSTATE CANCER AND PROSTATIC DISEASES
    14. Belldegrun, A; Shvarts, O; Figlin, RA
      Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    15. Hoffman, DMJ; Gitlitz, BJ; Belldegrun, A; Figlin, RA
      Adoptive cellular therapy

      SEMINARS IN ONCOLOGY
    16. Pantuck, AJ; Zisman, A; Rauch, MK; Belldegrun, A
      Incidental renal tumors

      UROLOGY
    17. Shvarts, O; Tsui, KH; Smith, RB; de Kernion, JB; Belldegrun, A
      Blood loss and the need for transfusion in patients who undergo partial orradical nephrectomy for renal cell carcinoma

      JOURNAL OF UROLOGY
    18. Tsui, KH; Shvarts, O; Smith, RB; Figlin, RA; deKernion, JB; Belldegrun, A
      Prognostic indicators for renal cell carcinoma: A multivariate analysis of643 patients using the revised 1997 TNM staging criteria

      JOURNAL OF UROLOGY
    19. Tsui, KH; Shvarts, O; Smith, RB; Figlin, R; DeKernion, JB; Belldegrun, A
      Renal cell carcinoma: Prognostic significance of incidentally detected tumors

      JOURNAL OF UROLOGY
    20. Tsui, KH; Shvarts, O; Barbaric, Z; Figlin, R; DeKernion, JB; Belldegrun, A
      Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies

      JOURNAL OF UROLOGY
    21. Pinthus, JH; Waks, T; Schindler, DG; Harmelin, A; Said, JW; Belldegrun, A; Ramon, J; Eshhar, Z
      WISH-PC2: A unique xenograft model of human prostatic small cell carcinoma

      CANCER RESEARCH
    22. Belldegrun, A
      What's hot in the prostate?

      PROSTATE CANCER AND PROSTATIC DISEASES
    23. van Ophoven, A; Ng, CP; Patel, B; Bonavida, B; Belldegrun, A
      Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature

      PROSTATE CANCER AND PROSTATIC DISEASES
    24. Belldegrun, A
      What's hot in the prostate?

      PROSTATE CANCER AND PROSTATIC DISEASES
    25. Belldegrun, A
      What's hot in the prostate?

      PROSTATE CANCER AND PROSTATIC DISEASES
    26. Belldegrun, A
      What's hot in the prostate?

      PROSTATE CANCER AND PROSTATIC DISEASES
    27. Mulders, P; Tso, CL; Gitlitz, B; Kaboo, R; Hinkel, A; Frand, S; Kiertscher, S; Roth, MD; deKernion, J; Figlin, R; Belldegrun, A
      Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines

      CLINICAL CANCER RESEARCH
    28. Belldegrun, A; Tsui, KH; deKernion, JB; Smith, RB
      Efficacy of nephron-sparing surgery for renal cell carcinoma: Analysis based on the new 1997 tumor-node-metastasis staging system

      JOURNAL OF CLINICAL ONCOLOGY
    29. Cangiano, T; Liao, J; Naitoh, J; Dorey, F; Figlin, R; Belldegrun, A
      Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy

      JOURNAL OF CLINICAL ONCOLOGY
    30. Frost, PJ; Belldegrun, A; Bonavida, B
      Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis

      PROSTATE
    31. Seltzer, MA; Barbaric, Z; Belldegrun, A; Naitoh, J; Dorey, F; Phelps, ME; Gambhir, SS; Hoh, CK
      Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer

      JOURNAL OF UROLOGY
    32. Naitoh, J; Kaplan, A; Dorey, F; Figlin, R; Belldegrun, A
      Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: Long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy

      JOURNAL OF UROLOGY
    33. Craft, N; Chhor, C; Tran, C; Belldegrun, A; DeKernion, J; Witte, ON; Said, J; Reiter, RE; Sawyers, CL
      Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process

      CANCER RESEARCH
    34. van Ophoven, A; Patel, B; Belldegrun, A; Hinkel, A; Senge, T
      Gene therapy and immunotherapy of advanced prostate cancer: from bench to bedside

      AKTUELLE UROLOGIE
    35. MULDERS P; TSO CL; PANG S; KABOO R; MCBRIDE WH; HINKEL A; GITLITZ B; DANNULL J; FIGLIN R; BELLDEGRUN A
      ADENOVIRUS-MEDIATED INTERLEUKIN-2 PRODUCTION BY TUMORS INDUCES GROWTHOF CYTOTOXIC TUMOR-INFILTRATING LYMPHOCYTES AGAINST HUMAN RENAL-CELL CARCINOMA

      Journal of immunotherapy
    36. BELLDEGRUN A
      WHATS HOT IN THE PROSTATE

      PROSTATE CANCER AND PROSTATIC DISEASES
    37. NAITOH J; BELLDEGRUN A
      GENE-THERAPY FOR PROSTATE-CANCER

      PROSTATE CANCER AND PROSTATIC DISEASES
    38. BELLDEGRUN A
      WHATS HOT IN THE PROSTATE

      PROSTATE CANCER AND PROSTATIC DISEASES
    39. MENA JO; NAITOH J; PALAPATTU G; BELLDEGRUN A
      THE ROLE OF INCIDENTAL ADRENALECTOMY DURING NEPHRECTOMY FOR RENAL-CELL CARCINOMA

      Journal of investigative medicine
    40. SELTZER M; BARBARIC Z; NAITOH J; CANGIANO T; DEKERNION J; BELLDEGRUN A; PHELPS M; HOH C
      IN-111 CAPROMAB PENDETIDE (PROSTASCINT) FALLS TO RELIABLY DETECT METASTASES IN PATIENTS BEFORE AND AFTER TREATMENT FOR LOCALIZED PROSTATE-CANCER

      The Journal of nuclear medicine
    41. NAITOH J; BELLDEGRUN A
      GENE-THERAPY - THE FUTURE IS HERE - A GUIDE TO THE PRACTICING UROLOGIST

      Urology
    42. SAROSDY MF; MANYAK MJ; SAGALOWSKY AI; BELLDEGRUN A; BENSON MC; BIHRLE W; CARROLL PR; ELLIS WJ; HUDSON MA; SHARKEY FE
      ORAL BROPIRIMINE IMMUNOTHERAPY OF BLADDER-CARCINOMA IN-SITU AFTER PRIOR INTRAVESICAL BACILLE-CALMETTE-GUERIN

      Urology
    43. NAITOH J; KABOO R; TSO CL; HINKEL A; STILES A; FIGLIN R; BELLDEGRUN A
      IMMUNOLOGICAL EFFECTS OF INTERLEUKIN-2 (IL-2) GENE-THERAPY IN PROSTATE-CANCER (CAP)

      The Journal of urology
    44. HINKEL A; GITLITZ BJ; KABOO R; MULDERS P; DEKEMION JB; FIGLIN RA; BELLDEGRUN A
      DENDRITIC CELL (DC) THERAPY FOR METASTATIC RENAL-CELL CANCER (MRCC) -FROM BASIC RESEARCH TO PHASE-I CLINICAL-TRIAL

      The Journal of urology
    45. HINKEL A; GITLITZ BJ; KABOO R; TSO CL; DEKERNION JB; FIGLIN RA; BELLDEGRUN A
      A NOVEL TECHNIQUE FOR GENERATING TUMOR LYSATE (TULY) LOADED DENDRITICCELLS (DC) FOR USE IN TUMOR VACCINE ADOPTIVE IMMUNOTHERAPY OR RENAL-CELL CANCER/

      The Journal of urology
    46. CANGIANO TG; LIAO JL; NAITOH J; DOREY F; FIGLIN R; BELLDEGRUN A
      SARCOMATOID VARIANT RENAL-CELL CARCINOMA - BIOLOGIC BEHAVIOR, PROGNOSIS, AND RESPONSE TO COMBINED SURGICAL RESECTION AND ADJUVANT IMMUNOTHERAPY

      The Journal of urology
    47. NAITOH J; TSO CL; KABOO R; STILES A; FIGLIN R; BELLDEGRUN A
      INTRAPROSTATIC INTERLEUKIN-2 (IL-2) GENE-THERAPY - PRELIMINARY-RESULTS OF A PHASE-I CLINICAL-TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED PROSTATE-CANCER (CAP)

      The Journal of urology
    48. SELTZER M; NAITOH J; CANGIANO T; ROSEN P; REITER R; DEKERNION J; BELLDEGRUN A; PHELPS M; HOH C
      COMPARISON OF COMPUTED-TOMOGRAPHY (CT), POSITRON-EMISSION-TOMOGRAPHY (PET), AND MONOCLONAL-ANTIBODY SCAN (MAB) FOR EVALUATION OF LYMPH-NODE(LN) METASTASES IN PATIENTS WITH PSA RELAPSE AFTER TREATMENT FOR LOCALIZED PROSTATE-CANCER (CAP)

      The Journal of urology
    49. HOH CK; SELTZER MA; FRANKLIN J; DEKERNION JB; PHELPS ME; BELLDEGRUN A
      POSITRON-EMISSION-TOMOGRAPHY IN UROLOGICAL ONCOLOGY

      The Journal of urology
    50. MULDERS P; PANG S; DANUULL J; KABOO R; HINKEL A; MICHEL K; TSO CL; ROTH M; BELLDEGRUN A
      HIGHLY EFFICIENT AND CONSISTENT GENE-TRANSFER INTO DENDRITIC CELLS UTILIZING A COMBINATION OF ULTRAVIOLET-IRRADIATED ADENOVIRUS AND POLY(L-LYSINE) CONJUGATES

      Cancer research
    51. BELLDEGRUN A
      DR WALSH,PATRICK VISITS IRELAND

      PROSTATE CANCER AND PROSTATIC DISEASES
    52. BELLDEGRUN A
      5 ALPHA-REDUCTASE INHIBITOR THERAPY REDUCES THE COMPLICATIONS OF BPH

      PROSTATE CANCER AND PROSTATIC DISEASES
    53. BELLDEGRUN A
      HOPE OF A NEW PROSTATE-CANCER VACCINE

      PROSTATE CANCER AND PROSTATIC DISEASES
    54. BELLDEGRUN A
      PROSTATE-CANCER CHARITABLE TRUST AWARD

      PROSTATE CANCER AND PROSTATIC DISEASES
    55. BELLDEGRUN A
      NEOADJUVANT HORMONAL ABLATION ENHANCES THE RESULTS OF RADIOTHERAPY

      PROSTATE CANCER AND PROSTATIC DISEASES
    56. BELLDEGRUN A
      WHATS IN THE PIPELINE

      PROSTATE CANCER AND PROSTATIC DISEASES
    57. FIGLIN R; GITLITZ B; FRANKLIN J; DOREY F; MOLDAWER N; RAUSCH J; DEKERNION J; BELLDEGRUN A
      INTERLEUKIN-2-BASED IMMUNOTHERAPY FOR THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA - AN ANALYSIS OF 203 CONSECUTIVELY TREATED PATIENTS

      The cancer journal from Scientific American
    58. KLEIN KA; REITER RE; REDULA J; MORAD H; ZHU XL; BROTHMAN AR; LAMB DJ; MARCELLI M; BELLDEGRUN A; WITTE ON; SAWYERS CL
      PROGRESSION OF METASTATIC HUMAN PROSTATE-CANCER TO ANDROGEN INDEPENDENCE IN IMMUNODEFICIENT SCID MICE

      Nature medicine
    59. USLU R; BORSELLINO N; FROST P; GARBAN H; NG CP; MIZUTANI Y; BELLDEGRUN A; BONAVIDA B
      CHEMOSENSITIZATION OF HUMAN PROSTATE CARCINOMA CELL-LINES TO ANTI-FAS-MEDIATED CYTOTOXICITY AND APOPTOSIS

      Clinical cancer research
    60. BONAVIDA B; SAFRIT J; MORIMOTO H; MIZUTANI Y; USLU R; BORSELLINO N; FROST P; BEREK J; BELLDEGRUN A; ZIGHELBOIM J; NG CP; MORI S
      CROSS-RESISTANCE OF TUMOR-CELLS TO CHEMOTHERAPY AND IMMUNOTHERAPY - APPROACHES TO REVERSE RESISTANCE AND IMPLICATIONS IN GENE-THERAPY (REVIEW)

      Oncology Reports
    61. FIGLIN R; MULDERS P; GITLITZ B; BELLDEGRUN A
      CELLULAR THERAPY OF RENAL-CELL CARCINOMA PAST, PRESENT, FUTURE

      European journal of cancer
    62. STEGER GG; GNANT MF; DJAVANMARD MP; MADER RM; JAKESZ R; PIERCE W; DEKERNION JB; FIGLIN R; BELLDEGRUN A
      THE IN-VITRO EFFECTS OF INTERLEUKIN-12 UPON TUMOR-INFILTRATING LYMPHOCYTES DERIVED FROM RENAL-CELL CARCINOMA

      Journal of cancer research and clinical oncology
    63. HOH CK; FIGLIN RA; SELTZER MA; BELLDEGRUN A; FRANKLIN J; GITLIZ B; PHELPS ME; MADDAHI J
      PROGNOSTIC VALUE OF A WHOLE-BODY FDG PET VS CONVENTIONAL IMAGING FOR THE EVALUATION OF BIOLOGIC THERAPY IN RENAL-CELL CARCINOMA

      The Journal of nuclear medicine
    64. FROST P; USLU R; BELLDEGRUN A; BONAVIDA B
      CHEMOSENSITIZATION OF HUMAN PROSTATE CARCINOMA CELL-LINES TO FAS-MEDIATED CYTOTOXICITY BY TIL

      Journal of allergy and clinical immunology
    65. FROST P; USLU R; BELLDEGRUN A; BONAVIDA B
      CD4 T-CELL MEDIATED APOPTOSIS OF MELANOMA-CELLS DOES NOT INVOLVE FAS CD95 PATHWAYS

      Journal of allergy and clinical immunology
    66. SYLJUASEN RG; BELLDEGRUN A; TSO CL; WITHERS HR; MCBRIDE WH
      SENSITIZATION OF RENAL-CARCINOMA TO RADIATION USING ALPHA-INTERFERON (IFNA) GENE TRANSFECTION

      Radiation research
    67. BELLDEGRUN A
      CYTOREDUCTIVE SURGERY BEFORE HIGH-DOSE INTERLEUKIN-2 BASED THERAPY INPATIENTS WITH METASTATIC RENAL-CELL CARCINOMA - EDITORIAL COMMENT

      The Journal of urology
    68. FIGLIN RA; PIERCE WC; KABOO R; TSO CL; MOLDAWER N; GITLITZ B; DEKERNION J; BELLDEGRUN A
      TREATMENT OF METASTATIC RENAL-CELL CARCINOMA WITH NEPHRECTOMY, INTERLEUKIN-2 AND CYTOKINE-PRIMED OR CD8(-INFILTRATING LYMPHOCYTES FROM PRIMARY TUMOR() SELECTED TUMOR)

      The Journal of urology
    69. FROST P; NG CP; BELLDEGRUN A; BONAVIDA B
      IMMUNOSENSITIZATION OF PROSTATE CARCINOMA CELL-LINES FOR LYMPHOCYTES (CTL, TIL, LAK)-MEDIATED APOPTOSIS VIA THE FAS-FAS-LIGAND PATHWAY OF CYTOTOXICITY

      Cellular immunology
    70. MULDERS P; FIGLIN R; DEKERNION JB; WILTROUT R; LINEHAN M; PARKINSON D; DEWOLF W; BELLDEGRUN A
      RENAL-CELL CARCINOMA - RECENT PROGRESS AND FUTURE-DIRECTIONS

      Cancer research
    71. BELLDEGRUN A; TSO CL; KABOO R; PANG S; PIERCE W; DEKERNION JB; FIGLIN R
      NATURAL IMMUNE REACTIVITY-ASSOCIATED THERAPEUTIC RESPONSE IN PATIENTSWITH METASTATIC RENAL-CELL CARCINOMA RECEIVING TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2-BASED THERAPY

      Journal of immunotherapy with emphasis on tumor immunology
    72. TOLOZA EM; HUNT K; SWISHER S; MCBRIDE W; LAU R; PANG S; RHOADES K; DRAKE T; BELLDEGRUN A; GLASPY J; ECONOMOU JS
      IN-VIVO CANCER GENE-THERAPY WITH A RECOMBINANT INTERLEUKIN-2 ADENOVIRUS VECTOR

      Cancer gene therapy
    73. ROSEN PJ; MENDOZA EF; LANDAW EM; MONDINO B; GRAVES MC; MCBRIDE JH; TURCILLO P; DEKERNION L; BELLDEGRUN A
      SURAMIN IN HORMONE-REFRACTORY METASTATIC PROSTATE-CANCER - A DRUG WITH LIMITED EFFICACY

      Journal of clinical oncology
    74. HOH CK; FIGLIN RA; BELLDEGRUN A; MOON DH; FRANKLIN J; PHELPS ME; MADDAHI J
      EVALUATION OF RENAL-CELL CARCINOMA WITH WHOLE-BODY FDG PET

      The Journal of nuclear medicine
    75. HOH CK; ROSEN PJ; BELLDEGRUN A; MOON DH; MADDAHI J; PHELPS ME
      QUANTITATIVE AND WHOLE-BODY FDG PET IN THE EVALUATION OF SURAMIN THERAPY IN PATIENTS WITH METASTATIC PROSTATE-CANCER

      The Journal of nuclear medicine
    76. SOKOLOFF MH; TSO CL; KABOO R; NELSON S; KO J; DOREY F; FIGLIN RA; PANG S; DEKERNION J; BELLDEGRUN A
      QUANTITATIVE POLYMERASE CHAIN-REACTION DOES NOT IMPROVE PREOPERATIVE PROSTATE-CANCER STAGING - A CLINICOPATHOLOGICAL MOLECULAR ANALYSIS OF 121 PATIENTS

      The Journal of urology
    77. NISHIKUBO CY; KUNKEL LA; FIGLIN R; BELLDEGRUN A; ROSEN P; ELASHOFF R; WANG HJ; TERRITO MC
      AN ASSOCIATION BETWEEN RENAL-CELL CARCINOMA AND LYMPHOID MALIGNANCIES- A CASE SERIES OF 8 PATIENTS

      Cancer
    78. SOKOLOFF MH; DEKERNION JB; FIGLIN RA; BELLDEGRUN A
      CURRENT MANAGEMENT OF RENAL-CELL CARCINOMA

      Ca
    79. BORSELLINO N; BELLDEGRUN A; BONAVIDA B
      IL-6 IS A RESISTANT FACTOR IN RESISTANT HUNAN PROSTATE-CANCER CELL-LINES AND ITS INHIBITION SENSITIZES THE CELLS TO CYTOTOXICITY BY CDDP

      The FASEB journal
    80. FIGLIN RA; GITLITZ BJ; BELLDEGRUN A
      IMMUNOLOGICAL APPROACHES TO THE TREATMENT OF CANCER

      Cancer investigation
    81. OLIVER RTD; BELLDEGRUN A; WRIGLEY PFM
      PREVENTING PROSTATE-CANCER - SCREENING VERSUS CHEMOPREVENTION - PROS AND CONS BASED ON NEW VIEWS OF ITS BIOLOGY, EARLY EVENTS AND CLINICAL BEHAVIOR - INTRODUCTION

      Cancer surveys
    82. ROSEN P; BELLDEGRUN A
      AMERICAN-STUDIES ON SURAMIN THERAPY IN HORMONE-RESISTANT PROSTATE-CANCER

      Cancer surveys
    83. TANEJA SS; PANG S; COHAN P; BELLDEGRUN A
      GENE-THERAPY - PRINCIPLES AND POTENTIAL

      Cancer surveys
    84. DEKERNION JB; FRANKLIN JR; BELLDEGRUN A; SMITH RB
      SURGERY FROM A US PERSPECTIVE

      Cancer surveys
    85. FIGLIN RA; BELLDEGRUN A
      RENAL-CELL CARCINOMA - INTRODUCTION

      Seminars in oncology
    86. PIERCE WC; BELLDEGRUN A; FIGLIN RA
      CELLULAR THERAPY - SCIENTIFIC RATIONALE AND CLINICAL-RESULTS IN THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA

      Seminars in oncology
    87. TANEJA SS; PIERCE W; FIGLIN R; BELLDEGRUN A
      IMMUNOTHERAPY FOR RENAL-CELL CARCINOMA - THE ERA OF INTERLEUKIN-2-BASED TREATMENT

      Urology
    88. BELLDEGRUN A; FRANKLIN JR; FIGLIN R
      COMMENTARY ON PROGNOSTIC FACTORS IN RENAL-CELL CARCINOMA

      The Journal of urology
    89. BORSELLINO N; BELLDEGRUN A; BONAVIDA B
      ENDOGENOUS INTERLEUKIN-6 IS A RESISTANCE FACTOR FOR CIS-DIAMMINEDICHLOROPLATINUM AND ETOPOSIDE-MEDIATED CYTOTOXICITY OF HUMAN PROSTATE CARCINOMA CELL-LINES

      Cancer research
    90. STEGER GG; KABOO R; DEKERNION JB; FIGLIN R; BELLDEGRUN A
      THE EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ON TUMOR-INFILTRATING LYMPHOCYTES FROM RENAL-CELL CARCINOMA

      British Journal of Cancer
    91. DOUGHERTY GJ; THACKER JD; LAVEY RS; BELLDEGRUN A; MCBRIDE WH
      INHIBITORY EFFECT OF LOCALLY PRODUCED AND EXOGENOUS INTERLEUKIN-6 ON TUMOR-GROWTH IN-VIVO

      Cancer immunology and immunotherapy
    92. TANEJA SS; PIERCE W; FIGLIN R; BELLDEGRUN A
      MANAGEMENT OF DISSEMINATED KIDNEY CANCER

      Urologic clinics of North America
    93. STEGER GG; PIERCE WC; FIGLIN R; CZERNIN J; KABOO R; DEKERNION JB; OKARMA T; BELLDEGRUN A
      PATTERNS OF CYTOKINE RELEASE OF UNSELECTED AND CD8-CELL CARCINOMA TUMOR-INFILTRATING LYMPHOCYTES (TIL) - EVIDENCE FOR ENHANCED SPECIFIC KILLING OF TUMOR NECROSIS FACTOR-SECRETING IL-6 NONSECRETING TIL IN-VITROAND CORRELATION WITH COMPLETE RESPONSE IN-VIVO( SELECTED RENAL)

      Clinical immunology and immunopathology
    94. HATHORN RW; TSO CL; KABOO R; PANG S; FIGLIN R; SAWYERS C; DEKERNION JB; BELLDEGRUN A
      IN-VITRO MODULATION OF THE INVASIVE AND METASTATIC POTENTIALS OF HUMAN RENAL-CELL CARCINOMA BY INTERLEUKIN-2 AND OR INTERFERON-ALPHA GENE-TRANSFER/

      Cancer
    95. ECONOMOU J; MILLER A; MCBRIDE W; SHAKED A; BELLDEGRUN A; ROSENBLATT J; GLASPY J; SCHILLER G; KOEFFLER P; SCHUCK B; RHOADES K; DOUGHERTY G; THACKER D; PRAGER M; VANBREE M; DRAZEN K; KOHN D; BAHNER I
      GENE-THERAPY PROGRAM AT UCLA

      Journal of cellular biochemistry
    96. FIGLIN RA; PIERCE WC; BELLDEGRUN A
      COMBINATION BIOLOGIC THERAPY WITH INTERLEUKIN-2 AND INTERFERON-ALFA IN THE OUTPATIENT TREATMENT OF METASTATIC RENAL-CELL CARCINOMA

      Seminars in oncology
    97. SELCH MT; MARK RJ; FU YS; BELLDEGRUN A; PARKER RG
      PRIMARY LYMPHOMA OF FEMALE URETHRA - LONG-TERM CONTROL BY RADIATION-THERAPY

      Urology
    98. PETZ LD; CALHOUN L; YAM P; CECKA M; SCHILLER G; FAITLOWICZ AR; HERRON R; SAYAH D; WALLACE RB; BELLDEGRUN A
      TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE IN IMMUNOCOMPETENT PATIENTS - REPORT OF A FATAL CASE ASSOCIATED WITH TRANSFUSION OF BLOOD FROM A 2ND-DEGREE RELATIVE, AND A SURVEY OF PREDISPOSING FACTORS

      Transfusion
    99. BELLDEGRUN A; PIERCE W; KABOO R; TSO CL; SHAU HY; TURCILLO P; MOLDAWER N; GOLUB S; DEKERNION J; FIGLIN R
      INTERFERON-ALPHA PRIMED TUMOR-INFILTRATING LYMPHOCYTES COMBINED WITH INTERLEUKIN-2 AND INTERFERON-ALPHA AS THERAPY FOR METASTATIC RENAL-CELL CARCINOMA

      The Journal of urology
    100. BELLDEGRUN A; PIERCE W; KABOO R; TSO CL; SHAU HY; TURCILLO D; MOLDAWER N; GOLLIB S; DEKERNION J; FIGLIN R
      THERAPY FOR METASTATIC RENAL-CELL CARCINOMA COMBINED WITH INTERLEUKIN-2 AND INTERFERON-ALPHA AS INTERFERON-ALPHA PRIMED TUMOR-INFILTRATING LYMPHOCYTES - REPLY

      The Journal of urology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 11:23:32